648 related articles for article (PubMed ID: 17968300)
21. Characteristics of KIT-negative gastrointestinal stromal tumours and diagnostic utility of protein kinase C theta immunostaining.
Lee HE; Kim MA; Lee HS; Lee BL; Kim WH
J Clin Pathol; 2008 Jun; 61(6):722-9. PubMed ID: 18381383
[TBL] [Abstract][Full Text] [Related]
22. Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs).
Sym SJ; Ryu MH; Lee JL; Chang HM; Kim TW; Kim HC; Kim KH; Yook JH; Kim BS; Kang YK
J Surg Oncol; 2008 Jul; 98(1):27-33. PubMed ID: 18452195
[TBL] [Abstract][Full Text] [Related]
23. KIT immunohistochemistry and mutation status in gastrointestinal stromal tumours (GISTs) evaluated for treatment with imatinib.
Loughrey MB; Trivett M; Beshay V; Dobrovic A; Kovalenko S; Murray W; Lade S; Turner H; McArthur GA; Zalcberg J; Waring PM
Histopathology; 2006 Jul; 49(1):52-65. PubMed ID: 16842246
[TBL] [Abstract][Full Text] [Related]
24. Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST).
Fiore M; Palassini E; Fumagalli E; Pilotti S; Tamborini E; Stacchiotti S; Pennacchioli E; Casali PG; Gronchi A
Eur J Surg Oncol; 2009 Jul; 35(7):739-45. PubMed ID: 19110398
[TBL] [Abstract][Full Text] [Related]
25. Factors associated with disease progression in patients with gastrointestinal stromal tumors in the pre-imatinib era.
Iesalnieks I; Rümmele P; Dietmaier W; Jantsch T; Zülke C; Schlitt HJ; Hofstädter F; Anthuber M
Am J Clin Pathol; 2005 Nov; 124(5):740-8. PubMed ID: 16203282
[TBL] [Abstract][Full Text] [Related]
26. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib.
Andtbacka RH; Ng CS; Scaife CL; Cormier JN; Hunt KK; Pisters PW; Pollock RE; Benjamin RS; Burgess MA; Chen LL; Trent J; Patel SR; Raymond K; Feig BW
Ann Surg Oncol; 2007 Jan; 14(1):14-24. PubMed ID: 17072676
[TBL] [Abstract][Full Text] [Related]
27. Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients.
Ménard C; Blay JY; Borg C; Michiels S; Ghiringhelli F; Robert C; Nonn C; Chaput N; Taïeb J; Delahaye NF; Flament C; Emile JF; Le Cesne A; Zitvogel L
Cancer Res; 2009 Apr; 69(8):3563-9. PubMed ID: 19351841
[TBL] [Abstract][Full Text] [Related]
28. Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression.
Liegl B; Hornick JL; Antonescu CR; Corless CL; Fletcher CD
Am J Surg Pathol; 2009 Feb; 33(2):218-26. PubMed ID: 18830121
[TBL] [Abstract][Full Text] [Related]
29. [Study on the mechanism of imatinib-induced resistance in gastrointestinal stromal tumors].
Zhou Y; Hou YY; Tan YS; Lu SH; Hou J; Liu JL; Qin J; Shen KT; Sun YH
Zhonghua Zhong Liu Za Zhi; 2009 Aug; 31(8):597-601. PubMed ID: 20021947
[TBL] [Abstract][Full Text] [Related]
30. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study.
Van Glabbeke M; Verweij J; Casali PG; Le Cesne A; Hohenberger P; Ray-Coquard I; Schlemmer M; van Oosterom AT; Goldstein D; Sciot R; Hogendoorn PC; Brown M; Bertulli R; Judson IR
J Clin Oncol; 2005 Aug; 23(24):5795-804. PubMed ID: 16110036
[TBL] [Abstract][Full Text] [Related]
31. Prognostic stratification of high-risk gastrointestinal stromal tumors in the era of targeted therapy.
Keun Park C; Lee EJ; Kim M; Lim HY; Choi DI; Noh JH; Sohn TS; Kim S; Kim MJ; Lee HK; Kim KM
Ann Surg; 2008 Jun; 247(6):1011-8. PubMed ID: 18520229
[TBL] [Abstract][Full Text] [Related]
32. [A case of metastatic gastrointestinal stromal tumor developing a resistance to STI571 (imatinib mesylate)].
Miyake M; Takeda Y; Hasuike Y; Kashiwazaki M; Mishima H; Ikenaga M; Mano M; Takada Y; Hirota S; Tsujinaka T
Gan To Kagaku Ryoho; 2004 Oct; 31(11):1791-4. PubMed ID: 15553717
[TBL] [Abstract][Full Text] [Related]
33. Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour - the impact of tumour rupture on patient outcomes.
Rutkowski P; Bylina E; Wozniak A; Nowecki ZI; Osuch C; Matlok M; Switaj T; Michej W; Wroński M; Głuszek S; Kroc J; Nasierowska-Guttmejer A; Joensuu H
Eur J Surg Oncol; 2011 Oct; 37(10):890-6. PubMed ID: 21737227
[TBL] [Abstract][Full Text] [Related]
34. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
Blanke CD; Rankin C; Demetri GD; Ryan CW; von Mehren M; Benjamin RS; Raymond AK; Bramwell VH; Baker LH; Maki RG; Tanaka M; Hecht JR; Heinrich MC; Fletcher CD; Crowley JJ; Borden EC
J Clin Oncol; 2008 Feb; 26(4):626-32. PubMed ID: 18235122
[TBL] [Abstract][Full Text] [Related]
35. Clinical outcome in gastrointestinal stromal tumor patients who interrupted imatinib after achieving stable disease or better response.
Lee JL; Ryu MH; Chang HM; Kim TW; Kang HJ; Sohn HJ; Lee JS; Kang YK
Jpn J Clin Oncol; 2006 Nov; 36(11):704-11. PubMed ID: 17068083
[TBL] [Abstract][Full Text] [Related]
36. Pleomorphic phenotypes of gastrointestinal stromal tumors at metastatic sites with or without imatinib treatment.
Sakamoto K; Sakurai S; Kanda T; Sakuma Y; Hishima T; Hironaka M; Bamba T; Keira Y; Takano Y; Niki T; Hasegawa T; Hirota S
Cancer Sci; 2010 May; 101(5):1270-8. PubMed ID: 20180814
[TBL] [Abstract][Full Text] [Related]
37. Gastrointestinal stromal tumors presenting as omental masses--a clinicopathologic analysis of 95 cases.
Miettinen M; Sobin LH; Lasota J
Am J Surg Pathol; 2009 Sep; 33(9):1267-75. PubMed ID: 19440146
[TBL] [Abstract][Full Text] [Related]
38. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors.
Demetri GD; Wang Y; Wehrle E; Racine A; Nikolova Z; Blanke CD; Joensuu H; von Mehren M
J Clin Oncol; 2009 Jul; 27(19):3141-7. PubMed ID: 19451435
[TBL] [Abstract][Full Text] [Related]
39. Management of gastrointestinal stromal tumors in the imatinib era: selected case studies.
Benjamin RS; Blanke CD; Blay JY; Bonvalot S; Eisenberg B
Oncologist; 2006 Jan; 11(1):9-20. PubMed ID: 16401709
[TBL] [Abstract][Full Text] [Related]
40. Advanced-stage gastrointestinal stromal tumor treated with imatinib in a 12-year-old girl with a unique mutation of PDGFRA.
Kuroiwa M; Hiwatari M; Hirato J; Suzuki N; Tsuchida Y; Shimada A; Shitara T; Taki T; Hayashi Y
J Pediatr Surg; 2005 Nov; 40(11):1798-801. PubMed ID: 16291174
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
